Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
At present 18 per cent of the local pharmaceutical market is under government's price control
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
SAB-185 is currently being evaluated in NIH-sponsored Phase 2/3 adaptive trial
This investment is being made to set up a high speed 400 vials a minute injectable fill line with isolator technology
Subscribe To Our Newsletter & Stay Updated
